导航
Search
Confirm
Cancel
NEWS
Check category
Homepage
>
News
>
普方生物宣布将在第33届国际分子靶标与癌症治疗大会上展示其旨在扩大抗体偶联药物（ADC）治疗窗口的新型药物连接子技术

普方生物宣布将在第33届国际分子靶标与癌症治疗大会上展示其旨在扩大抗体偶联药物（ADC）治疗窗口的新型药物连接子技术

  • Categories:News
  • Author:
  • Origin:
  • Time of issue:2021-10-09
  • Views:0

(Summary description)普方生物宣布将在第33届国际分子靶标与癌症治疗大会上展示其旨在扩大抗体偶联药物（ADC）治疗窗口的新型药物连接子技术

普方生物宣布将在第33届国际分子靶标与癌症治疗大会上展示其旨在扩大抗体偶联药物（ADC）治疗窗口的新型药物连接子技术

(Summary description)普方生物宣布将在第33届国际分子靶标与癌症治疗大会上展示其旨在扩大抗体偶联药物（ADC）治疗窗口的新型药物连接子技术

  • Categories:News
  • Author:
  • Origin:
  • Time of issue:2021-10-09
  • Views:0

Scan the QR code to read on your phone

Previous: ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
Next: ProfoundBio Completed $55+ Million USD Series A Financing
Previous: ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
Next: ProfoundBio Completed $55+ Million USD Series A Financing

Contact us

Address：Suite 101&102, Bldg 1, P3A, 1 Xinze Street, SIP, Suzhou, China
E-mail：info@profoundbio.com

email

E-mail

info@profoundbio.com

TEL

+86-574-88193874

Wechat

Scan to add
Tenglong Wechat

Copyright © 2021 ProfoundBio (Suzhou) Co., Ltd.   All rights reserved. 苏ICP备2021002620号 Powered by www.300.cn